State Key Laboratory of Medical Genomics, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrinology and Metabolism, Endocrine and Metabolic E-Institutes of Shanghai Universities, and Key Laboratory for Endocrinology and Metabolism of Chinese Health Ministry, Rui-jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China.
Am J Cardiol. 2010 Nov 15;106(10):1461-5. doi: 10.1016/j.amjcard.2010.07.013. Epub 2010 Oct 1.
Osteocalcin, a bone-derived polypeptide, was recently found to have hormonal function associated with metabolic disorders and atherosclerosis. Few studies have examined the association between circulating osteocalcin and coronary heart disease (CHD) risk. The aim of the present study was to investigate whether serum osteocalcin concentration was associated with CHD risk and metabolic profiles in Chinese adults. A total of 461 subjects (243 with CHD and 218 without CHD) who underwent coronary angiography were included. Serum osteocalcin, glucose, lipid profiles, and other biochemical markers were measured. Severity of coronary atherosclerosis was estimated by number of diseased vessels. Results showed that serum osteocalcin levels were significantly lower in the CHD group (12.2 ng/ml, 9.5 to 15.1) than in the non-CHD group (13.6 ng/ml, 10.7 to 18.0, p = 0.001) and were significantly decreased with the increasing of number of diseased vessels (p = 0.005). Serum osteocalcin concentration was inversely correlated with fasting and post load 2 hour plasma glucose and hemoglobin A(1c) (p = 0.044, 0.043, and 0.011, respectively), adjusting for CHD status. Odds ratios (95% confidence intervals) of CHD across increasing quartiles of serum osteocalcin were 0.68 (0.42 to 1.12), 0.59 (0.36 to 0.98), and 0.40 (0.23 to 0.69). The test for trend was significant (p = 0.0007). Adjusting for age, body mass index, and other conventional risk factors for CHD did not appreciably change the results. Spline regression analyses indicated a linear relation between serum osteocalcin level and CHD risk. In conclusion, our data indicate that serum osteocalcin level was associated with decreased risk of CHD and protective metabolic changes in Chinese adults.
骨钙素,一种来源于骨骼的多肽,最近被发现具有与代谢紊乱和动脉粥样硬化相关的激素功能。很少有研究探讨循环骨钙素与冠心病(CHD)风险之间的关系。本研究旨在探讨血清骨钙素浓度与中国成年人 CHD 风险和代谢特征的关系。共纳入 461 例接受冠状动脉造影的患者(243 例 CHD,218 例非 CHD)。检测血清骨钙素、血糖、血脂谱和其他生化标志物。通过病变血管数量评估冠状动脉粥样硬化严重程度。结果显示,CHD 组血清骨钙素水平明显低于非 CHD 组(12.2ng/ml,9.515.1)(p=0.001),且随病变血管数量的增加而显著降低(p=0.005)。血清骨钙素浓度与空腹和餐后 2 小时血浆葡萄糖和糖化血红蛋白 A1c 呈负相关(p=0.044、0.043 和 0.011),校正 CHD 状态后仍有统计学意义。按血清骨钙素四分位数递增,CHD 的优势比(95%可信区间)分别为 0.68(0.421.12)、0.59(0.360.98)和 0.40(0.230.69)。趋势检验有统计学意义(p=0.0007)。校正年龄、体重指数和其他 CHD 的常规危险因素后,结果无明显变化。分段回归分析表明血清骨钙素水平与 CHD 风险呈线性关系。结论:本研究数据表明,血清骨钙素水平与 CHD 风险降低和中国成年人保护性代谢变化相关。